UbiVac LLC Profile last edited on: 1/14/19
CAGE: 4GYJ8
UEI: MC47NKBQ8A25
Business Identifier: Immunotherapies to combat cancer. 
Is this YOUR Company?
Ensure accuracy and completeness of YOUR Company Profile by completing the brief Survey Instrument attached
Do you know about this Awardees?
Let us encourage you to provide any data which would enhance the completeness of this firm's profile.
Location Information
Location: Single
Congr. District: 01
County: Washington
Congr. District: 01
County: Washington
Public Profile
UbiVac LLC is developing a new cancer vaccine technology based on hormones and enzymes produced by tumor cells. UbiVac is a development stage biotechnology company that is focused on discovering, licensing, improving and commercializing immunotherapy products that safely generate and augment the immune response to vaccines. Preclinical studies document that UbiVac technology is significantly more effective than current âgold standard vaccines at inducing tumor regression and increasing survival of tumor-bearing hosts. Based on these data a phase I clinical trial of UbiVac vaccine technology will be initiated in patients with non-small cell lung cancer (NSCLC) in the first quarter of 2008. UbiVac is also exploring the application of this approach to the development of an avain flu vaccine
Extent of SBIR involvement
Synopsis: Awardee Business Condition
Employee Range
5-9Revenue Range
.5M-1MVC funded?
NoPublic/Private
Privately HeldStock Info
----IP Holdings
1-4Awards Distribution by Agency
Most Recent SBIR Projects
| Year | Phase | Agency | Total Amount | |
|---|---|---|---|---|
| 2014 | 2 | NIH | $288,718 | |
| Project Title: Aluminum Oxide Nanoparticles Conjugated to Antigens Potently Induce Tumor Specifi | ||||
| 2013 | 2 | NIH | $3,527,726 | |
| Project Title: New Cancer Vaccine Technology Based on DRibbles Produced by Tumor Cells | ||||
Key People / Management
Bernard A Fox -- President & CEO
Sandra Aung
Steve Buhaly -- Chief Financial Officer
Bernard A Fox III -- Chief Operating Officer
Traci Leigh Hilton -- Vice President of Vaccine Development
Hong-Ming Hu -- Chief Scientific Officer
Sandra Aung
Steve Buhaly -- Chief Financial Officer
Bernard A Fox III -- Chief Operating Officer
Traci Leigh Hilton -- Vice President of Vaccine Development
Hong-Ming Hu -- Chief Scientific Officer
